Stuart Therapeutics Spotlights Topical RP Program - Report - MDSpire

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

  • By

  • Eric Schlumpf

  • July 15, 2026

  • 2 min

Share

Clinical Report: Stuart Therapeutics Spotlights Topical RP Program

Overview

Stuart Therapeutics is developing a topical therapy for retinitis pigmentosa (RP) using a collagen mimetic peptide platform. Preclinical studies in nonhuman primates show retinal penetration.

Background

Retinitis pigmentosa is a group of inherited retinal diseases leading to progressive vision loss. Current treatment options are limited.

Data Highlights

Preclinical studies demonstrate topical drop penetration throughout the posterior retina, including the retinal extracellular matrix region.

Key Findings

  • Stuart Therapeutics is focusing on a collagen mimetic peptide platform for RP.
  • The therapy aims to provide neuroprotective effects and reduce inflammation.
  • Topical application is designed to improve the overall health of the posterior retina.
  • Preclinical data shows effective penetration of the therapy in nonhuman primates.
  • The program is in preclinical development stages.

Clinical Implications

The development of a topical therapy for RP may offer a new treatment avenue.

Conclusion

Stuart Therapeutics is developing a topical collagen mimetic peptide for retinitis pigmentosa.

Related Resources & Content

  1. Stuart Therapeutics, OIS Retina, 2026 -- Stuart Therapeutics Spotlights Topical RP Program
  2. the ophthalmologist — Optogenetic RP Therapy Gains RMAT
  3. Retinal Physician — SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit, developments in gene therapy, research on IRD, and more.
  4. Retinal Physician — Subspecialty News April 2024
  5. Retinal Physician — Retinal Physician eUpdate - February 16, 2024
  6. Optogenetic RP Therapy Gains RMAT
  7. SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit
  8. Subspecialty News April 2024
  9. ICER Report on Retinitis Pigmentosa
  10. EudraCT Number 2020-002873-88 - Clinical trial results - EU Clinical Trials Register
  11. Our Pipeline – Stuart Therapeutics

Original Source(s)

Stuart Therapeutics Spotlights Topical RP Program

  • by Eric Schlumpf

  • July 15, 2026

Related Content

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

Retinal Age Model Tied to Disease Risk

Fundus-based tool estimates biologic aging but shows modest gains over prior models

Blindness Linked to Higher Loneliness Scores

Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.